A preservative-free version of Lumigan gel led to IOP reductions comparable to a preserved version of the ophthalmic solution, with a lower rate of treatment-related ocular adverse events.The study, ...
Many medicines get second shot when they have useful or desirable side effects. Dec. 29, 2008 — -- Some people might look at Meiko Catron, a native of Japan, and find her tilted eyes exotic and ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. LONDON — Lumigan (AGN 192024, Allergan) once daily ...
The Food and Drug Administration has approved Amneal’s bimatoprost ophthalmic solution 0.01% (2.5 ml, 5 ml and 7.5 ml), which is the generic of Allergan’s Lumigan. Bimatoprost ophthalmic solution 0.01 ...
Firm projects Lumigan product sales will total $490–$510 million in 2010. FDA has approved Allergan’s Lumigan® 0.01% bimatoprost solution as first-line therapy for reducing intraocular pressure (IOP) ...
In Allergan, Inc. v. Sandoz, Inc., the Federal Circuit affirmed the district court decision that upheld the validity of the Allergan patents relating to Lumigan® 0.01% glaucoma eye drops. This ...
Eye drops used to treat glaucoma hold the key to a cure for baldness. Researchers have found bimatoprost, a key ingredient in the Lumigan drug, increases hair growth. The drug is given as eye drops to ...
Patent-cliff worries have been weighing on Allergan ($AGN) as of late, but a Texas judge has allayed some of those concerns--at least for now. That judge upheld U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback